Epitope - based peptide vaccine against glycoprotein G of <i>Nipah henipavirus</i> using immunoinformatics approaches

Mohammed, Arwa A.; Shantier, Shaza W.; Mustafa, Mujahed I.; Osman, Hind K.; Elmansi, Hashim E.; Osman, Isam-Aldin A.; Mohammed, Rawan A.; Abdelrhman, Fatima A.; Elnnewery, Mihad E.; Yousif, Einas M.; Mustafa, Marwa M.; Elfadol, Nafisa M.; Abdalla, Alaa I.; Mahmoud, Eiman M; Eltay, Ahmed A.; Ahmed, Yassir A.; Hassan, Mohamed A.

doi:10.1101/678664

Cited by 5 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total 33 CD8+ T cell epitopes were finally selected. From this list 10 CTL epitopes (Fusion Protein: FALSNGVLF; Glycoprotein: TVYHCSAVY; Nucleocapsid: YPALALNEF; Phosphoprotein: VSDAKMLSY; Polymerase: YPECNNILF, FPVMGNRIY, AEFFSFFRTF, IPFLFLSAY, ETDDYNGIY, SQNLLVTSY) show a match with previous studies [35–38], indicating consensus of epitope screening by different approaches and methods (Supplementary table S3).…”

Section: Resultssupporting

confidence: 75%

“…AEFFSFFRTF, IPFLFLSAY, ETDDYNGIY, SQNLLVTSY) show a match with previous studies[35][36][37][38], indicating consensus of epitope screening by different approaches and methods (Supplementary table…”

supporting

confidence: 83%

“…Along with the B cell, the T cell also play a critical role in immune response against NiV infection. In recent studies a number of B cell and T cell epitopes from the NIPAH proteome have been reported [27][28][29][30][31][32][33][34][35][36][37][38]. Further different approaches were proposed for the design of multi epitope vaccines [39,44].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Exploring the structural basis to develop efficient multi-epitope vaccines displaying interaction with HLA and TAP and TLR3 molecules to prevent NIPAH infection, a global threat to human health

Srivastava

Saxena

Kolbe

2021

Preprint

View full text Add to dashboard Cite

Nipah virus (NiV) is an emerging zoonotic virus responsible to cause several serious outbreaks in South Asian region with high mortality rate of 40 to 90% since 2001. NiV infection causes lethal encephalitis and respiratory disease with the symptom of endothelial cell-cell fusion. No specific vaccine has yet been reported against NiV infection. Recently, some Multi-Epitope Vaccines (MEV) has been proposed but they involve limited number of epitopes which further limits the potential of vaccine. To address the urgent need for a specific and effective vaccine against NiV infection, in the present study, we have design two multi-epitope vaccines (MEVs) composed of 33 Cytotoxic T lymphocyte (CTL) epitopes and 38 Helper T lymphocyte (HTL) epitopes. Both the MEVs carry potential B cell linear epitope overlapping regions, B cell discontinuous epitopes as well as IFN-γ inducing epitopes. Hence the designed MEVs carry potential to elicit cell-mediated as well as humoral immune response. Selected CTL and HTL epitopes were validated for their stable molecular interactions with HLA class I and II alleles as well as in case of CTL epitopes, with human transporter associated with antigen processing (TAP). Human β-defensin 2 and β-defensin 3 were used as adjuvants to enhance the immune response of both the MEVs. The molecular dynamics simulation study of MEVs-TLR3(ECD) (Toll-Like Receptor 3 Ectodomain) complex indicated stable molecular interaction. Further, the codon optimized cDNA of both the MEVs has shown high expression potential in the mammalian host cell line (Human). Hence for further studies, both the design of CTL and HTL MEVs could be cloned, expressed and tried for in-vivo validations (animal trails) as potential vaccine candidates against NiV infection.

show abstract

Section: Resultssupporting

confidence: 75%

supporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exploring the structural basis to develop efficient multi-epitope vaccines displaying interaction with HLA and TAP and TLR3 molecules to prevent NIPAH infection, a global threat to human health

Srivastava

Saxena

Kolbe

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…All these proteins are potential targets for rational drug design. Some studies in the recent past have targeted epitopes of these viral proteins [31,32]. However, to the best of our knowledge, the whole proteome modeling of NiV for drug discovery has not been attempted.…”

Section: Introductionmentioning

confidence: 99%

Predicting and designing therapeutics against the Nipah virus

et al. 2019

View full text Add to dashboard Cite

Despite Nipah virus outbreaks having high mortality rates (>70% in Southeast Asia), there are no licensed drugs against it. In this study, we have considered all 9 Nipah proteins as potential therapeutic targets and computationally identified 4 putative peptide inhibitors (against G, F and M proteins) and 146 small molecule inhibitors (against F, G, M, N, and P proteins). The computations include extensive homology/ab initio modeling, peptide design and small molecule docking. An important contribution of this study is the increased structural characterization of Nipah proteins by approximately 90% of what is deposited in the PDB. In addition, we have carried out molecular dynamics simulations on all the designed protein-peptide complexes and on 13 of the top shortlisted small molecule ligands to check for stability and to estimate binding strengths. Details, including atomic coordinates of all the proteins and their ligand bound complexes, can be accessed at http://cospi.iiserpune.ac.in/Nipah. Our strategy was to tackle the development of therapeutics on a proteome wide scale and the lead compounds identified could be attractive starting points for drug development. To counter the threat of drug resistance, we have analysed the sequences of the viral strains from different outbreaks, to check whether they would be sensitive to the binding of the proposed inhibitors.

show abstract

“…13 Further, the same approach was applied by Mohammed et al (2019) in which they have used the NiV G protein. 14 Both studies have exploited one or three proteins for NiV subunit vaccine designing, but this study included more number of proteins, and the epitopes were also vary from each other. Therefore, we can say that the designed vaccine will be more immunogenic and efficacious against the NiV infection.…”

Section: Introductionmentioning

confidence: 99%

Strategic Development of a Next-Generation Multi-Epitope Vaccine To Prevent Nipah Virus Zoonotic Infection

et al. 2019

View full text Add to dashboard Cite

Nipah virus (NiV) is an emerging zoonotic pathogen, reported for the recent severe outbreaks of encephalitis and respiratory illness in humans and animals, respectively. Many antiviral drugs have been discovered to inhibit this pathogen, but none of them were that much efficient. To overcome the complications associated with this severe pathogenic virus, we have designed a multi-epitope subunit vaccine using computational immunology strategies. Identification of structural and nonstructural proteins of Nipah virus assisted in the vaccine designing. The selected proteins are known to be involved in the survival of the virus. The antigenic binders (B-cell, HTL, and CTL) from the selected proteins were prognosticated. These antigenic binders will be able to generate the humoral as well as cell-mediated immunity. All the epitopes were united with the help of suitable linkers and with an adjuvant at the N-terminal of the vaccine, for the enhancement of immunogenicity. The physiological characterization, along with antigenicity and allergenicity of the designed vaccine candidates, was estimated. The 3D structure prediction and its validation were performed. The validated vaccine model was then docked and simulated with the TLR-3 receptor to check the stability of the docked complex. This next-generation approach will provide a new vision for the development of a high immunogenic vaccine against the NiV.

show abstract

Epitope - based peptide vaccine against glycoprotein G of Nipah henipavirus using immunoinformatics approaches

Cited by 5 publications

References 50 publications

Exploring the structural basis to develop efficient multi-epitope vaccines displaying interaction with HLA and TAP and TLR3 molecules to prevent NIPAH infection, a global threat to human health

Exploring the structural basis to develop efficient multi-epitope vaccines displaying interaction with HLA and TAP and TLR3 molecules to prevent NIPAH infection, a global threat to human health

Predicting and designing therapeutics against the Nipah virus

Strategic Development of a Next-Generation Multi-Epitope Vaccine To Prevent Nipah Virus Zoonotic Infection

Contact Info

Product

Resources

About